A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1
1,006
about 8.8 years
18+
106 sites in AK, AR, CA +16
What this study is about
Researchers are testing sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to determine its safety and effectiveness in people with solid tumors. The trial will also evaluate the side effects of sigvotatug vedotin and assess whether it works to treat these cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take carboplatin
- 2.Take cisplatin
- 3.Take pembrolizumab
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
injection, intravenous, infusion
Primary: Number of participants with adverse events (AEs), Number of participants with dose-limiting toxicities (DLTs)
Secondary: Apparent terminal elimination half-life (t1/2), Area under the concentration-time curve (AUC), Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator assessment, Duration of objective response (DOR) per RECIST v1.1 by investigator assessment, Maximum observed concentration (Cmax), Overall survival (OS), Progression-free survival (PFS) per RECIST v1.1 by investigator assessment, Time to maximum observed concentration (Tmax)
Oncology